Cohance Lifesciences shareholders have approved key resolutions including the appointment of Umang Vohra as Chairman and Group CEO, and the Employee Stock Option Plan 2026. This signals a leadership transition and new incentive structure.

Cohance Lifesciences Approves Leadership and ESOP Scheme

Cohance Lifesciences Limited shareholders have overwhelmingly approved five key resolutions, including the appointment of Umang Vohra as Chairman and Group CEO, and the introduction of the Employee Stock Option Plan (ESOP) 2026.

Reader Takeaway: New leadership and ESOP approved; signals strategic alignment and future equity dilution.

What just happened

Through a postal ballot e-voting process, members of Cohance Lifesciences Limited cast their votes on five significant resolutions. The outcomes show substantial approval for the proposed changes, including leadership appointments and a new employee incentive plan.

Why this matters

These resolutions formalize critical leadership changes and introduce a new equity-based incentive structure. The appointment of Mr. Umang Vohra to key leadership roles and the implementation of ESOP 2026 are significant strategic moves that will shape the company's future governance and employee engagement.

The backstory

This vote follows the company's decision to implement a new leadership structure and an employee stock option plan. The postal ballot process allowed shareholders to express their consent remotely.

What changes now

Mr. Umang Vohra is set to take on the role of Chairman from May 1, 2026, and Group Chief Executive Officer from May 20, 2026. The ESOP 2026 plan, including its extension to subsidiaries and specific grant authorities, is now officially approved and can be implemented.

Risks to watch

Investors will need to monitor the impact of the ESOP 2026 on potential equity dilution. The approved remuneration for Mr. Vohra exceeding Section 197 limits will also be a point of observation.

Peer comparison

While not explicitly detailed in the filing, ESOPs are common among pharmaceutical and life sciences companies in India to attract and retain talent. The scale and specifics of Cohance's plan will determine its competitive positioning.

Context metrics (time-bound)

• Chairman & Group CEO Appointment: Effective May 1, 2026 (Chairman) and May 20, 2026 (Group CEO).
• ESOP 2026 Approval: Approved via postal ballot.
• Remuneration Approval: Exceeds limits under Section 197 of the Companies Act, 2013.
• Grant Authority: Options to grant >= 1% of issued capital in a single year approved.

What to track next

Investors should look for announcements regarding the specific implementation details of ESOP 2026 and monitor the company's equity structure in future financial reports. The performance under the new leadership will also be key.